Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics

Psychedelics companies are all the rage right now. Compass Pathways is working with the magic mushroom compound psilocybin to treat depression. It’s has raised $290 million in total. Atai Life Sciences — backed by PayPal co-founder Peter Thiel — brought in $258 million from its IPO. In the tech space, this has not gone unnoticed and the same business models that have been used in other platforms for health and wellness startups are coming to psychedelics.

The latest is Journey Clinical, based out of NYC, which has raised a $3 million seed round led by San Francisco VC firm Fifty Years. Also participating were Neo Kuma Ventures, Palo Santo,

→ Continue reading at TechCrunch

More from author

Related posts

Advertisment

Latest posts

Ransomware attack on Planned Parenthood exposes 400,000 patients' personal data

The unidentified perpetrator stole documents from the Planned Parenthood affiliate that contained sensitive data on some patients such as their insurance information, their diagnosis,...

Improving Employee Collaboration in the Post-Pandemic Workplace

Opinions expressed by Entrepreneur contributors are their own. When I founded Netskope nine years ago, I decided that no matter how much...

How to participate in Shark Tank México, step by step guide

This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process. Do you think you...